Table 1.
Patient and disease characteristics
| Rigosertib twice daily dosing (mg) |
||||||
|---|---|---|---|---|---|---|
| 70 | 140 | 280 | 560 | 700 | Total | |
| Patients | 3 | 2 | 3 | 33 | 7a | 48 |
| Sex | M1/F2 | F2 | M2/F1 | M15/F18 | M6/F1 | M24/F24 |
| Age (range) | 49–74 | 57–63 | 51–60 | 20–79 | 47–71 | 20–79 |
| Colorectal carcinoma | 10 | 10 | ||||
| HNSCC | 1 | 3 | 2 | 6 | ||
| Ovarian carcinoma | 2 | 2 | 4 | |||
| Esophageal adenocarcinoma | 4 | 4 | ||||
| Renal cell carcinoma | 3 | 3 | ||||
| Hepatocellular carcinoma | 2 | 2 | ||||
| Breast carcinoma | 1 | 1a | 2 | |||
| Uterine adenocarcinoma | 1 | 1 | ||||
| Uterine carcinosarcoma | 1 | 1 | ||||
| Leiomyosarcoma | 1 | |||||
| Cervical adenocarcinoma | 1 | 1 | ||||
| Transitional cell carcinoma | 1 | 1 | ||||
| Pancreatic neuroendocrine | 1 | 1 | ||||
| Vulvovaginal melanoma | 1 | 1 | ||||
| Carcinoid tumor | 1 | 1 | ||||
| Salivary gland carcinoma | 1 | 1 | ||||
| Gastrointestinal stromal tumor | 1 | 1 | ||||
| Craniopharyngioma | 1 | 1 | ||||
| Adrenocortical carcinoma | 1 | 1 | ||||
| SCC lung | 1 | |||||
| Osteosarcoma | 1 | |||||
| Prostate carcinoma | 1 | 1 | ||||
| SCC vulva | 1 | |||||
| Adenoid cystic nasopharyngeal | 1 | 1 | ||||
a
One patient in the 700-mg cohort was taken off study for progression 2 days after starting treatment and replaced by an additional patient treated at this dose level.